Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Shares Outstanding (Diluted Average) (2021 - 2025)

Arcus Biosciences has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $107.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $107.4 million for Q4 2025, up 19.2% from a year ago — trailing twelve months through Dec 2025 was $107.4 million (up 19.2% YoY), and the annual figure for FY2025 was $107.4 million, up 19.2%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $107.4 million at Arcus Biosciences, up from $106.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for RCUS hit a ceiling of $107.4 million in Q4 2025 and a floor of $71.2 million in Q1 2022.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $74.0 million (2021), compared with a mean of $84.1 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): fell 2.7% in 2022 and later grew 24.45% in 2024.
  • Arcus Biosciences' Shares Outstanding (Diluted Average) stood at $74.0 million in 2021, then fell by 2.7% to $72.0 million in 2022, then grew by 2.78% to $74.0 million in 2023, then increased by 21.76% to $90.1 million in 2024, then grew by 19.2% to $107.4 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $107.4 million (Q4 2025), $106.5 million (Q3 2025), and $106.5 million (Q2 2025) per Business Quant data.